Mersana Therapeutics Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics or view top-rated stocks.

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Mersana Therapeutics.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its quarterly earnings results on Friday, February, 26th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.09. The company earned $0.01 million during the quarter, compared to analysts' expectations of $0.43 million. Mersana Therapeutics had a negative net margin of 8,772.91% and a negative trailing twelve-month return on equity of 45.16%.
View Mersana Therapeutics' earnings history.

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRSN stock has increased by 157.7% and is now trading at $16.65.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 12-month target prices for Mersana Therapeutics' shares. Their forecasts range from $18.00 to $33.00. On average, they anticipate Mersana Therapeutics' share price to reach $26.17 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price.
View analysts' price targets for Mersana Therapeutics or view top-rated stocks among Wall Street analysts.

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Mersana Therapeutics include Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), I-Mab (IMAB), Arena Pharmaceuticals (ARNA), Hypera (HYPMY), Agios Pharmaceuticals (AGIO), Atea Pharmaceuticals (AVIR), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Nektar Therapeutics (NKTR), Legend Biotech (LEGN), PTC Therapeutics (PTCT), Insmed (INSM) and ACADIA Pharmaceuticals (ACAD).
View all of MRSN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology Group (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRSN stock can currently be purchased for approximately $16.65.

Mersana Therapeutics has a market capitalization of $1.15 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

Mersana Therapeutics employs 110 workers across the globe.

The official website for Mersana Therapeutics is www.mersana.com.

Mersana Therapeutics is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]